Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy by Fabian Zohren, Ingmar.

Slides:



Advertisements
Similar presentations
Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,
Advertisements

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,
EBV-positive diffuse large B-cell lymphoma of the elderly by Chi Young Ok, Thomas G. Papathomas, L. Jeffrey Medeiros, and Ken H. Young Blood Volume 122(3):
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study by Eric Van Den Neste, Christian.
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.
A Randomized Trial Of Daily Prednisone Versus Pulsed Dexamethasone In Treatment Naïve Patients With Idiopathic Thrombocytopenic Purpura by Johannes Matschke,
Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens.
Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura
بهداشت فردي.
Finding a diamond in the (mouse is) rough
by James O. Armitage, and Dan L. Longo
Next-generation leukemia immunotherapy
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
Treatment of Severe Hemorrhagic Cystitis after Allogeneic Stem Cell Transplantation with Palifermin, a Recombinant Human Keratinocyte Growth Factor  Akos.
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Clofarabine Salvage Therapy Prior To Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Relapsed Or Refractory AML – Results Of The Bridge.
Tax fingerprint in adult T-cell leukemia
How I treat elderly patients with myeloma
Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,
Positron Emission Tomography in Non-Hodgkin's Lymphoma: Assessment of Chemotherapy With Fluorodeoxyglucose by Wolfgang Römer, Axel-R. Hanauske, Sibylle.
Nonmyeloablative conditioning for relapsed follicular lymphoma
by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu
A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease by Sten Myrehaug, Melania Pintilie, Lingsong.
What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):
by Wolfram Springer, Alexander von Ruecker, and Roswitha Dickerhoff
Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,
by Jessica A. Reese, Xiaoning Li, Manfred Hauben, Richard H
JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.
by Alexander Röth, Andreas Hüttmann, Russell P
by Fangxin Hong, Thomas M Habermann, Leo I
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma.
Primary testicular lymphoma
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial by Peter Dreger,
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,
Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index by Chor-Sang Chim, Shing-Yan.
Has MRD monitoring superseded other prognostic factors in adult ALL?
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience by Daryl Tan, Sandra.
Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.
How I treat refractory CLL
Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies by Sabine Kayser, Manuela Zucknick,
The Level of Minimal Residual Disease in the Bone Marrow of Patients with Multiple Myeloma before High-Dose Therapy and Autologous Blood Stem Cell Transplantation.
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy by Vindi Jurinovic, Robert Kridel, Annette.
Upfront Allogeneic Blood Stem Cell Transplantation for Patients with High-Risk Myelodysplastic Syndrome or Secondary Acute Myeloid Leukemia Using a FLAMSA-
Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,
Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma  Mark Korthals, Nina Sehnke, Ralf Kronenwett,
by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc
Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte.
Superiority of Obinutuzumab over Rituximab in a New Molecular Follicular Lymphoma-like Subgroup of DLBCL: Results from an Exploratory Analysis of the Phase.
by Wendy Lim, Sara K. Vesely, and James N. George
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Impact of age on clinical risk scores in follicular lymphoma
11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment.
Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.
Optimizing therapy for nodal marginal zone lymphoma
Is Skull-Base to Proximal Thigh PET/CT Enough
Cold agglutinin disease
Outcomes in patients with PTCL
Presentation transcript:

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy by Fabian Zohren, Ingmar Bruns, Sabrina Pechtel, Thomas Schroeder, Roland Fenk, Akos Czibere, Georg Maschmeyer, Dorothea Kofahl-Krause, Norbert Niederle, Gerhard Heil, Christoph Losem, Manfred Welslau, Wolfram Brugger, Ulrich Germing, Ralf Kronenwett, Juergen Barth, Mathias J. Rummel, Rainer Haas, and Guido Kobbe Blood Volume 126(12): September 17, 2015 ©2015 by American Society of Hematology

Consolidated Standards of Reporting Trials diagram. Fabian Zohren et al. Blood 2015;126: ©2015 by American Society of Hematology

Pretreatment Bcl-2/IgH status and level. Fabian Zohren et al. Blood 2015;126: ©2015 by American Society of Hematology

Posttreatment Bcl-2/IgH status and level. Fabian Zohren et al. Blood 2015;126: ©2015 by American Society of Hematology

Follow-up Bcl-2/IgH status and level. Fabian Zohren et al. Blood 2015;126: ©2015 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.